Bioscience Humility vs AI Acceleration

Leading bioscientists interviewed (e.g., Jennifer Doudna, Craig Venter) foreground the complexity and uncertainty of biology and therefore prefer precautionary approaches, even as AI communities push rapid scale and deployment. That cultural divide (risk‑sensitive bioscience vs speed‑focused AI) shapes how societies will accept, regulate, and fund different technologies. — Recognizing this cultural difference reframes regulatory and public‑trust debates: policy should not treat AI and gene editing as identical regulatory problems because research cultures, failure modes, and stakes differ.